

INFORMAZIONI PERSONALI

Giuseppe Morgia

 Via Santa Sofia 78 – Catania

 +39 095/3782710  -----

 gmorgia@policlinico.unict.it

 <http://www.giuseppemorgia.it/>

Sesso Maschile | Data di nascita 08/11/1959 | Nazionalità Italiana | CF MRGGPP59S08C351L | Nato a Catania

ESPERIENZE LAVORATIVE

01/11/2009 sino ad oggi

Professore Ordinario presso l'Università degli Studi di Catania

Direttore dell'U.O.C. di Urologia dell'A.O.U. "Policlinico-Vittorio Emanuele", P.O. "G. Rodolico"
Direttore della Scuola di Specializzazione d'Urologia dell'Università degli Studi di Catania

Settore Sanità

Dal 01/12/2006 al 31/10/2009

Professore Ordinario presso l'Università degli Studi di Messina

Direttore dell'U.O.C. di Urologia dell'A.O.U. Policlinico "G. Martino".
Direttore della Scuola di Specializzazione d'Urologia dell'Università degli Studi di Messina

Settore Sanità

Dal 01/11/2001 al 30/11/2006

Professore Ordinario presso l'Università degli Studi di Sassari

Direttore dell'U.O.C. di Urologia del Policlinico di Sassari.
Direttore della Scuola di Specializzazione d'Urologia dell'Università degli Studi di Sassari

Settore Sanità

Anno Accademico 2011-2012

Vice Direttore presso il Master di II livello in "Innovazioni tecnologiche in chirurgia laparoscopica avanzata"

Facoltà di Medicina e Chirurgia - Università La Sapienza, Roma

FORMAZIONE

Novembre 1994

Specializzazione in Urologia

50/50 e lode

Università degli studi di Catania

▪ Urology

Novembre 1989

Specializzazione in Chirurgia Generale

50/50 e lode

Università degli studi di Catania

04/07/84

Laurea in Medicina e Chirurgia

110/110

Università degli studi di Catania

28 aprile-7 maggio 1995

Clinical Observer Dipartimento di Urologia della University of California, San Francisco (U.S.C.F.).

110/110

Dipartimento di Urologia della University of California, San Francisco (U.S.C.F.).

ABILITA' PERSONALI

Lingua Madre Italiano

Altre Lingue

Inglese

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
B2	B2	B2	B2	B2

Communication skills

Abilità manageriali Direttore di Unità Operativa Complessa

Abilità Informatiche Comuni

Licenza di guida B

INFORMAZIONI AGGIUNTIVE

Pubblicazioni

1. Endocrine control of benign prostatic hyperplasia. La Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. *Andrology*. 2016 Apr 18. doi: 10.1111/andr.12186..
2. Re: Complex link between male lower urinary tract symptoms and metabolic syndrome: More than ethnic disparity. Urzi D, Russo GI, Morgia G. *Int J Urol*. 2016 May;23(5):437. doi: 10.1111/iju.13092. Epub 2016 Apr 4. No abstract available.
3. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, Fragalà E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M. *BMJ Open*. 2016 Mar 31;6(3):e009669. doi: 10.1136/bmjopen-2015-009669.
4. Editorial comment to The efficacy of acupuncture in managing patients with chronic prostatitis/chronic pelvic pain syndrome: A systemic review and meta-analysis. Russo GI, Cimino S, Morgia G. *Neurourol Urodyn*. 2016 Feb 24. doi: 10.1002/nau.22977. [Epub ahead of print] No abstract available.
5. Partial Nephrectomy in Clinical T1b Renal Tumors: Multicenter Comparative Study of Open, Laparoscopic and Robot-assisted Approach (the RECORd Project). Porpiglia F, Mari A, Bertolo R, Antonelli A, Bianchi G, Fidanza F, Fiori C, Furlan M, Morgia G, Novara G, Rocco B, Rovereto B, Serni S, Simeone C, Carini M, Minervini A. *Urology*. 2016 Mar;89:45-53. doi: 10.1016/j.urology.2015.08.049. Epub 2015 Dec 29.
6. Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. Fragalà E, Russo GI, Di Rosa A, Giardina R, Privitera S, Favilla V, Patti F, Welk B, Cimino S, Castelli T, Morgia G. *Int Neurourol J*. 2015 Dec;19(4):272-7. doi: 10.5213/inj.2015.19.4.272. Epub 2015 Dec 28.

7. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients. Russo GI, Vanella L, Castelli T, Cimino S, Reale G, Urzi D, Li Volti G, Gacci M, Carini M, Motta F, Caltabiano R, Puzzo L, Sorrenti V, Morgia G. *World J Urol.* 2015 Nov 30. [Epub ahead of print]
8. Correction of Retrograde Ejaculation in Patients with Diabetes Mellitus Using Endourethral Collagen Injection: Preliminary Results. Kurbatov D, Russo GI, Galstyan GR, Rozhivanov R, Lepetukhin A, Dubsky S, Shwartz YG, Cimino S, Morgia G, Sansalone S. *J Sex Med.* 2015 Nov;12(11):2126-9. doi: 10.1111/jsm.13024. Epub 2015 Nov 9.
9. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. La Vignera S, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. *Aging Male.* 2016 Mar;19(1):34-9. doi: 10.3109/13685538.2015.1092021. Epub 2015 Oct 21.
10. Acquired premature ejaculation and male accessory gland infection : relevance of ultrasound examination. La Vignera S, Condorelli RA, Vicari E, Favilla V, Morgia G, Calogero AE. *Asian J Androl.* 2015 Sep 18. doi: 10.4103/1008-682X.155539. [Epub ahead of print]
11. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I(125) implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Morgia G, Castelli T, Privitera S, Al-Nakib C, Favilla V, Marchese F, Cimino S, Russo GI. *Aging Male.* 2016 Mar;19(1):15-9. doi: 10.3109/13685538.2015.1083546. Epub 2015 Sep 16.
12. Response to Editorial Comment from Dr Cantiello and Dr Damiano to Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. Russo GI, Morgia G. *Int J Urol.* 2015 Nov;22(11):993. doi: 10.1111/iju.12945. Epub 2015 Sep 7. No abstract available.
13. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, Mantini G, Gontero P, Savoca G, Ficarra V; (Members of the LUNA Foundation, Società Italiana d'Urologia). *BJU Int.* 2015 Aug 31. doi: 10.1111/bju.13307. [Epub ahead of print]
14. Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis. Russo GI, Di Rosa A, Favilla V, Fragalà E, Castelli T, Privitera S, Cimino S, Morgia G. *Can Urol Assoc J.* 2015 May-Jun;9(5-6):E359-66. doi: 10.5489/cuaj.2479.
15. Predicting erectile dysfunction in sexually active patients seeking prostate health screening: proposal for a multivariable risk stratification. Favilla V, Russo GI, Reale G, Leone S, Castelli T, La Vignera S, Condorelli RA, Calogero AE, Cimino S, Morgia G. *Int J Impot Res.* 2015 Nov-Dec;27(6):201-5. doi: 10.1038/ijir.2015.15. Epub 2015 Jul 30.
16. Prostatic Arterial Embolization vs Open Prostatectomy: A 1-Year Matched-pair Analysis of Functional Outcomes and Morbidities. Russo GI, Kurbatov D, Sansalone S, Lepetukhin A, Dubsky S, Sitkin I, Salamone C, Fiorino L, Rozhivanov R, Cimino S, Morgia G. *Urology.* 2015 Aug;86(2):343-8. doi: 10.1016/j.urology.2015.04.037. Epub 2015 Jul 18.
17. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. Cantiello F, Russo GI, Cicione A, Ferro

- M, Cimino S, Favilla V, Perdonà S, De Cobelli O, Magno C, Morgia G, Damiano R. *World J Urol.* 2016 Apr;34(4):485-93. doi: 10.1007/s00345-015-1643-z. Epub 2015 Jul 21.
18. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. Russo GI, Castelli T, Urzi D, Privitera S, La Vignera S, Condorelli RA, Calogero AE, Favilla V, Cimino S, Morgia G. *Int J Urol.* 2015 Nov;22(11):982-90. doi: 10.1111/iju.12877. Epub 2015 Jul 20. Review.
 19. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Russo GI, Castelli T, Urzi D, Privitera S, Fragalà E, La Vignera S, Condorelli RA, Calogero AE, Favilla V, Cimino S, Morgia G. *Aging Male.* 2015;18(4):207-16. doi: 10.3109/13685538.2015.1062980. Epub 2015 Jul 14.
 20. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria. Russo GI, Castelli T, Favilla V, Reale G, Urzi D, Privitera S, Fragalà E, Cimino S, Morgia G. *Prostate Cancer Prostatic Dis.* 2015 Dec;18(4):338-42. doi: 10.1038/pcan.2015.26. Epub 2015 Jun 2.
 21. Benign prostatic hyperplasia and metabolic syndrome: the expanding evidences of a new disease of aging male. Russo GI, Cimino S, Morgia G. *Aging Male.* 2015;18(3):133-4. doi: 10.3109/13685538.2015.1028353. Epub 2015 Jun 1. No abstract available.
 22. Different levels of Cd45pos leukocytes in the semen of patients with low testicular volume. La Vignera S, Condorelli RA, Morgia G, Favilla V, Russo GI, Cimino S, Vicari E, Calogero AE. *Int J Immunopathol Pharmacol.* 2015 Mar;28(1):85-92. doi: 10.1177/0394632015572748.
 23. Contemporary Role of Testis Sparing Surgery: A Systematic Review
Russo GI*, Reale G, Privitera S, Castelli T, Madonia M, Cimino S, Favilla V, Morgia G. *EMJ Urol.* 2015;3[1]:34-40.
 24. How to define cumulative cancer length for selecting candidate for active surveillance? Russo GI*, Morgia G. *J Clin Pathol.* 2015 May;68(5):323-4. doi: 10.1136/jclinpath-2014-202786
 25. Different levels of Cd45pos leukocytes in the semen of patients with low testicular volume. La Vignera S, Condorelli RA, Morgia G, Favilla V, Russo GI, Cimino S, Vicari E, Calogero AE. *Int J Immunopathol Pharmacol.* 2015 Mar;28(1):85-92. doi: 10.1177/0394632015572748
 26. Benign prostatic hyperplasia and metabolic syndrome: the expanding evidences of a new disease of aging male. Russo GI, Cimino S, Morgia G. *Aging Male.* 2015 Sep;18(3):133-4
 27. Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria. Russo GI, Castelli T, Favilla V, Reale G, Urzi D, Privitera S, Fragalà E, Cimino S, Morgia G. *Prostate Cancer Prostatic Dis.* 2015 Dec;18(4):338-42.
 28. Accuracy capabilities comparisons between karakiewicz, kattan and cindolo nomograms in predicting outcomes for renal cancer carcinoma: a systematic review and meta-analysis. Russo GI, Di Rosa A, Favilla V, Fragalà E, Castelli T, Privitera S, Cimino S, Morgia G. *Can J Urol.* 2015 May-June; 9(5-6): E359-66
 29. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Russo GI, Castelli T, Urzi D, Privitera S, Fragalà E, La Vignera S, Condorelli RA, Calogero AE, Favilla V, Cimino S, Morgia G. *Aging Male.* 2015 Jul 14:1-10.
 30. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. Russo GI, Castelli T, Urzi D,

- Privitera S, La Vignera S, Condorelli RA, Calogero AE, Favilla V, Cimino S, Morgia G. *Int J Urol*. 2015 Nov;22(11):982-90.
31. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. Cantiello F, Russo GI, Cicione A, Ferro M, Cimino S, Favilla V, Perdonà S, De Cobelli O, Magno C, Morgia G, Damiano R. *World J Urol*. 2015 Jul 21.
 32. Prostatic Arterial Embolization vs Open Prostatectomy: A 1-Year Matched-pair Analysis of Functional Outcomes and Morbidities. Russo GI, Kurbatov D, Sansalone S, Lepetukhin A, Dubsky S, Sitkin I, Salamone C, Fiorino L, Rozhivanov R, Cimino S, Morgia G. *Urology*. 2015 Aug;86(2):343-8.
 33. Predicting erectile dysfunction in sexually active patients seeking prostate health screening: proposal for a multivariable risk stratification. Favilla V, Russo GI*, Reale G, Leone S, Castelli T, La Vignera S, Condorelli RA, Calogero AE, Cimino S, Morgia G. *Int J Impot Res*. 2015 Nov;27(6):201-5
 34. Patterns of prescription and adherence to EAU Guidelines of androgen deprivation therapy in prostate cancer: an Italian multicenter cross-sectional analysis from the CHOInG treatment for prostate canCER (CHOICE) study. Morgia G, Russo GI*, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, Mantini G, Gontero P, Savoca G, Ficarra V; Members of LUNA Foundation, Società Italiana d'Urologia. *BJU Int*. 2015 Aug 31. doi: 10.1111/bju.13307.
 35. Response to Editorial Comment from Dr Cantiello and DrDamiano to Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review. Russo GI, Morgia G. *Int J Urol*. 2015 Sep 7. doi: 10.1111/iju.12945
 36. Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I¹²⁵ implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Morgia G, Castelli T, Privitera S, Al-Nakib C, Favilla V, Marchese F, Cimino S, Russo GI. *Aging Male*. 2015 Sep 16:1-5
 37. Reproductive function in male patients with type 1 diabetes mellitus. La Vignera S, Condorelli RA, Di Mauro M, Lo Presti D, Mongioi LM, Russo G, Calogero AE. *Andrology*. 2015 Oct 7. doi: 10.1111/andr.12097
 38. Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone. La Vignera S, Condorelli RA, Cimino L, Russo GI, Morgia G, Calogero AE. *Aging Male*. 2015 Oct 21:1-6
 39. Varicocele and concomitant dilation of the periprostatic venous plexus: effects on semen viscosity sperm parameters. Condorelli RA, Calogero AE, Mongioi L, Vicari E, Russo GI, Lanzafame F, La Vignera S. *J Endocrinol Invest*.
 40. Correction of Retrograde Ejaculation in Patients with Diabetes Mellitus Using Endourethral Collagen Injection: Preliminary Results. Kurbatov D, Russo GI, Galstyan GR, Rozhivanov R, Lepetukhin A, Dubsky S, Shwartz YG, Cimino S, Morgia G, Sansalone S. *J Sex Med*. 2015 Nov 9.
 41. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients. Russo GI, Vanella L, Castelli T, Cimino S, Reale G, Urzi D, Li Volti G, Gacci M, Carini M, Motta F, Caltabiano R, Puzzo L, Sorrenti V, Morgia G. *World J Urol*. 2015 Nov 30
 42. Single-session Supine Bilateral Percutaneous Nephrolithotomy. Proietti S, Sortino G, Giannantoni A, Sofer M, Peschechera R, Luciani LG, Morgia G, Giusti G. *Urology*. 2015 Feb;85(2):304-10. doi: 10.1016/j.urology.2014.10.036.

43. Increase of Framingham risk score is associated with severity of Lower urinary tract symptoms. Russo GI, Castelli T, Privitera S, Fragalà E, Favilla V, Reale G, Urzi D, La Vignera S, Condorelli R, Calogero AE, Cimino S, Morgia G.
BJU Int. 2015 Jan 20. doi: 10.1111/bju.13053.
44. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F, Russo GI, Ferro M, Cicione A, Cimino S, Favilla V, Perdonà S, Bottero D, Terracciano D, De Cobelli O, **Morgia G**, Damiano R.
Urol Oncol. 2015 Jan 6. pii: S1078-1439(14)00448-7. doi: 10.1016/j.urolonc.2014.12.002.
45. A snapshot of nephron-sparing surgery in Italy: A prospective, multicenter report on clinical and perioperative outcomes (the RECORD 1 project).
Schiavina R, Mari A, Antonelli A, Bertolo R, Bianchi G, Borghesi M, Brunocilla E, Fiori C, Longo N, Martorana G, Mirone V, **Morgia G**, Novara G, Porpiglia F, Rovereto B, Serni S, Simeone C, Sodano M, Terrone C, Carini M, Minervini A.
Eur J Surg Oncol. 2014 Dec 27. pii: S0748-7983(14)01286-4. doi: 10.1016/j.ejso.2014.12.001.
46. A Prospective, Multicenter Evaluation of Predictive Factors for Positive Surgical Margins After Nephron-Sparing Surgery for Renal Cell Carcinoma: The RECORD1 Italian Project.
Schiavina R, Serni S, Mari A, Antonelli A, Bertolo R, Bianchi G, Brunocilla E, Borghesi M, Carini M, Longo N, Martorana G, Mirone V, **Morgia G**, Porpiglia F, Rocco B, Rovereto B, Simeone C, Sodano M, Terrone C, Ficarra V, Minervini A.
Clin Genitourin Cancer. 2014 Sep 23. pii: S1558-7673(14)00201-8. doi: 10.1016/j.clgc.2014.08.008.
47. Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction.
Fragalà E, Russo GI, Di Rosa A, Giardina R, Privitera S, Favilla V, Castelli T, Chisari M, Caramma A, Patti F, Cimino S, **Morgia G**. Eur J Neurol. 2014 Nov 19. doi: 10.1111/ene.12595.
48. Male accessory gland infection: relevance of serum total testosterone levels.
Condorelli RA, Calogero AE, Vicari E, Favilla V, Cimino S, Russo GI, **Morgia G**, La Vignera S.
Int J Endocrinol. 2014;2014:915752. doi: 10.1155/2014/915752. Epub 2014 Sep
49. Oxidative stress and body composition in prostate cancer and benign prostatic hyperplasia patients.
Cimino S, Favilla V, Russo GI, Galvano F, Li Volti G, Barbagallo I, Giofrè SV, D'Orazio N, Di Rosa A, Madonia M, **Morgia G**.
Anticancer Res. 2014 Sep;34(9):5051-6.
50. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study.
Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, Calogero AE, Chisari M, Castelli T, Favilla V, **Morgia G**.
World J Urol. 2014 Sep 5.
51. The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome.
Racioppi M, Salmaso L, Brombin C, Arboretti R, D'Agostino D, Colombo R, Serretta V, Brausi M, Casetta G, Gontero P, Hurle R, Tenaglia R, Altieri V, Bartoletti R, Maffezzini M, Siracusano S, **Morgia G**, Bassi PF.
Urol Int. 2014 Aug 27.

52. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
Morgia G, Russo GI, Voce S, Palmieri F, Gentile M, Giannantoni A, Blefari F, Carini M, Minervini A, Ginepri A, Salvia G, Vespasiani G, Santelli G, Cimino S, Allegro R, Collura Z, Fragalà E, Arnone S, Pareo RM.
 Prostate. 2014 Nov;74(15):1471-80. doi: 10.1002/pros.22866. Epub 2014 Aug 23.
53. TriMatch comparison of the efficacy of FloSeal versus TachoSil versus no hemostatic agents for partial nephrectomy: Results from a large multicenter dataset.
 Antonelli A, Minervini A, Mari A, Bertolo R, Bianchi G, Lapini A, Longo N, Martorana G, Mirone V, **Morgia G**, Novara G, Porpiglia F, Rocco B, Rovereto B, Schiavina R, Simeone C, Sodano M, Terrone C, Ficarra V, Carini M, Semi S; RECORd Project-LUNA Foundation.
 Int J Urol. 2015 Jan;22(1):47-52. doi: 10.1111/iju.12603. Epub 2014 Aug 19
54. Alga Ecklonia bicyclis, Tribulus terrestris, and glucosamine oligosaccharide improve erectile function, sexual quality of life, and ejaculation function in patients with moderate mild-moderate erectile dysfunction: a prospective, randomized, placebo-controlled, single-blinded study.
 Sansalone S, Leonardi R, Antonini G, Vitarelli A, Vespasiani G, Basic D, **Morgia G**, Cimino S, Russo GI.
 Biomed Res Int. 2014;2014:121396. doi: 10.1155/2014/121396. Epub 2014 Jul 20.
55. Functional characterization of platelets in patients with arterial erectile dysfunction.
 La Vignera S, Condorelli RA, Burgio G, Vicari E, Favilla V, Russo GI, Cimino S, **Morgia G**, Calogero AE.
 Andrology. 2014 Sep ;2(5):709-15. doi: 10.1111/j.2047-2927.2014.00255.x. Epub 2014 Jul 29
56. Determinants of sexual impairment in multiple sclerosis in male and female patients with lower urinary tract dysfunction: results from an italian cross-sectional study.
 Fragalà E, Privitera S, Giardina R, Di Rosa A, Russo GI, Favilla V, Caramma A, Patti F, Cimino S, **Morgia G**.
 J Sex Med. 2014 Oct;11(10):2406-13. doi: 10.1111/jsm.12635. Epub 2014 Jul 11
57. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.
 Castelli T, Russo GI, Favilla V, Urzi D, Spitaleri F, Reale G, Giardina R, Saita A, Madonia M, Cimino S, **Morgia G**.
 Int Braz J Urol. 2014 May-Jun;40(3):322-9. doi: 10.1590/S1677-5538.IBJU.2014.03.05.
58. Prevalence of Intratubular Germ Cell Neoplasia and Multifocality in Testicular Germ Cell Tumors ≤ 2 cm: Relationship With Other Pathological Features.
 Favilla V, Russo GI, Spitaleri F, Urzi D, Madonia M, La Vignera S, Condorelli R, Calogero AE, Cimino S, **Morgia G**.
 Clin Genitourin Cancer. 2015 Feb;13(1):e31-5. doi: 10.1016/j.clgc.2014.06.009. Epub 2014 Jun 11.
59. Prostatic artery embolization for prostate volume greater than 80 cm³: results from a single-center prospective study.
 Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, **Morgia G**, Rozhivanov R, Cimino S, Sansalone S.
 Urology. 2014 Aug;84(2):400-4. doi: 10.1016/j.urology.2014.04.028. Epub 2014 Jun 12.
60. The gonadal function in obese adolescents: review.

Condorelli RA, Calogero AE, Vicari E, Mongioi' L, Favilla V, **Morgia G**, Cimino S, Russo G, La Vignera S.
J Endocrinol Invest. 2014 Jun 13.

61. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia.
Vanella L, Russo GI, Cimino S, Fragalà E, Favilla V, Li Volti G, Barbagallo I, Sorrenti V, **Morgia G**.
Urology. 2014 Jun;83(6):1444.e7-13. doi: 10.1016/j.urology.2014.03.007.
62. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study.
Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, Calogero AE, Castelli T, Favilla V, **Morgia G**.
J Sex Med. 2014 Aug;11(8):2074-82. doi: 10.1111/jsm.12587. Epub 2014 May 19
63. 5ARI and PSA: evidences.
Morgia G, Urzi D, Russo GI.
Urologia. 2014 Sep 23;81 Suppl 24:4-11. doi: 10.5301/urologia.5000068. Italian.
64. Inhibitors of apoptosis proteins in experimental benign prostatic hyperplasia: effects of serenoa repens, selenium and lycopene.
Minutoli L, Altavilla D, Marini H, Rinaldi M, Irrera N, Pizzino G, Bitto A, Arena S, Cimino S, Squadrito F, Russo GI, **Morgia G**.
J Biomed Sci. 2014 Mar 10;21:19. doi: 10.1186/1423-0127-21-19.
65. Reduced Seminal Concentration of CD45pos Cells after Follicle-Stimulating Hormone Treatment in Selected Patients with Idiopathic Oligoasthenoteratozoospermia.
Condorelli RA, Calogero AE, Vicari E, Mongioi' L, Burgio G, Cannarella R, Giaccone F, Iacoviello L, **Morgia G**, Favilla V, Cimino S, La Vignera S.
Int J Endocrinol. 2014;2014:372060. doi: 10.1155/2014/372060. Epub 2014 Jan 14.
66. Simple enucleation versus standard partial nephrectomy for clinical T1 renal masses: perioperative outcomes based on a matched-pair comparison of 396 patients (RECORD project).
Longo N, Minervini A, Antonelli A, Bianchi G, Bocciardi AM, Cunico SC, Fiori C, Fusco F, Giancane S, Mari A, Martorana G, Mirone V, **Morgia G**, Novara G, Porpiglia F, Raspollini MR, Rocco F, Rovereto B, Schiavina R, Serni S, Simeone C, Verze P, Volpe A, Ficarra V, Carini M.
Eur J Surg Oncol. 2014 Jun;40(6):762-8. doi: 10.1016/j.ejso.2014.01.007. Epub 2014 Feb 1.
67. Pneumatic lithotripsy versus holmium:YAG laser lithotripsy for the treatment of single ureteral stones: a prospective, single-blinded study.
Cimino S, Favilla V, Russo GI, Saita A, Sortino G, Castelli T, Veroux M, Madonia M, **Morgia G**.
Urol Int. 2014;92(4):468-72. doi: 10.1159/000355828. Epub 2014 Jan 28.
68. Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): a 12 months follow-up.
Favilla V, Cimino S, Salamone C, Fragalà E, Madonia M, Condorelli R, La Vignera S, Mongioi' L, Pirozzi Farina F, Russo GI, **Morgia G**.
J Endocrinol Invest. 2013 Dec;36(11):1094-8.
69. An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst® Gold Study.

- Cai T, **Morgia G**, Carrieri G, Terrone C, Imbimbo C, Verze P, Mirone V; IDIProst® Gold Study Group. Arch Ital Urol Androl. 2013 Dec 31;85(4):184-9. doi: 10.4081/aiua.2013.4.184.
70. A case of gross haematuria due to an ureteric-iliac artery fistula.
Madonia M, Russo GI, Trignano E, Paliogiannis P, Cimino S, Corbu C, **Morgia G**.
Ann Ital Chir. 2013 Dec 23;84(ePub). pii: S2239253X13021750.
71. Multifocality in testicular germ cell tumor (TGCT): what is the significance of this finding?
Favilla V, Russo GI, Spitaleri F, Urzi D, Garau M, Madonia M, Saita A, Pirozzi Farina F, La Vignera S, Condorelli R, Calogero AE, Cimino S, **Morgia G**.
Int Urol Nephrol. 2014 Jun;46(6):1131-5. doi: 10.1007/s11255-013-0617-6. Epub 2013 Dec 7.
72. A multicentre matched-pair analysis comparing robot-assisted versus open partial nephrectomy.
Ficarra V, Minervini A, Antonelli A, Bhayani S, Guazzoni G, Longo N, Martorana G, **Morgia G**, Mottrie A, Porter J, Simeone C, Vittori G, Zattoni F, Carini M.
BJU Int. 2014 Jun;113(6):936-41. doi: 10.1111/bju.12570. Epub 2014 May 22.
73. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
Russo GI, Cimino S, Castelli T, Favilla V, Urzi D, Veroux M, Madonia M, **Morgia G**.
Urol Oncol. 2014 Apr;32(3):291-6. doi: 10.1016/j.urolonc.2013.07.004. Epub 2013 Nov 1.
74. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study.
Favilla V, Russo GI, Privitera S, Castelli T, Madonia M, La Vignera S, Condorelli R, Calogero AE, Farina FP, Cimino S, **Morgia G**.
Andrologia. 2014 Oct;46(8):936-42. doi: 10.1111/and.12178. Epub 2013 Oct 11.
75. Genito-urological cancers in elderly patients.
Morgia G, Russo GI, Berretta M, Privitera S, Kirkali Z.
Anticancer Agents Med Chem. 2013 Nov;13(9):1391-405. Review.
76. Microbiological investigation in male infertility: a practical overview.
La Vignera S, Condorelli RA, Vicari E, Salmeri M, **Morgia G**, Favilla V, Cimino S, Calogero AE.
77. J Med Microbiol. 2014 Jan;63(Pt 1):1-14. doi: 10.1099/jmm.0.062968-0. Epub 2013 Sep 26. Review.
78. Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORD Project).
Minervini A, Siena G, Antonelli A, Bianchi G, Bocciardi AM, Cosciani Cunico S, Ficarra V, Fiori C, Fusco F, Mari A, Martorana G, Medica M, Mirone V, **Morgia G**, Porpiglia F, Rocco F, Rovereto B, Schiavina R, Simeone C, Terrone C, Volpe A, Carini M, Serni S; Members of the RECORD Project-LUNA Foundation.
World J Urol. 2014 Feb;32(1):257-63. doi: 10.1007/s00345-013-1155-7. Epub 2013 Sep 7.
79. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).
Brookman-May SD, May M, Shariat SF, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, **Morgia G**, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project; Members of the SATURN-Project; Young Academic Urologists Renal Cancer Group.
BJU Int. 2013 Nov;112(7):909-16. doi: 10.1111/bju.12246. Epub 2013 Jul 25.
80. Does the neobladder filling modulate soleus H reflex?

- Palleschi G, Conte A, Pastore AL, Salerno G, **Morgia G**, Giannantoni A, Berardelli A, Carbone A. Clin Neurophysiol. 2014 Feb;125(2):425-7. doi: 10.1016/j.clinph.2013.06.027. Epub 2013 Jul 19.
81. Markers of semen inflammation: supplementary semen analysis?
La Vignera S, Condorelli RA, Vicari E, Tumino D, **Morgia G**, Favilla V, Cimino S, Calogero AE. J Reprod Immunol. 2013 Nov;100(1):2-10. doi: 10.1016/j.jri.2013.05.001. Epub 2013 Jul 10. Review.
82. The semen quality of the mobile phone users.
Rago R, Salacone P, Caponecchia L, Sebastianelli A, Marcucci I, Calogero AE, Condorelli R, Vicari E, **Morgia G**, Favilla V, Cimino S, Arcoria AF, La Vignera S. J Endocrinol Invest. 2013 Dec;36(11):970-4. doi: 10.3275/8996. Epub 2013 May 30.
83. Potential efficacy of some african plants in benign prostatic hyperplasia and prostate cancer.
Russo GI, Cimino S, Salamone C, Madonia M, Favilla V, Castelli T, **Morgia G**. Mini Rev Med Chem. 2013 Oct;13(11):1564-71. Review.
84. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study.
Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T. Int Braz J Urol. 2013 Mar-Apr;39(2):214-21. doi: 10.1590/S1677-5538.IBJU.2013.02.10.
85. Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches.
Condorelli RA, Calogero AE, Vicari E, Favilla V, **Morgia G**, Cimino S, La Vignera S. Andrology. 2013 Jul;1(4):533-40. doi: 10.1111/j.2047-2927.2013.00087.x. Epub 2013 May 8. Review.
86. Prevalence of male accessory gland inflammations/infections in patients with Type 2 diabetes mellitus.
Condorelli RA, Calogero AE, Vicari E, Duca Y, Favilla V, **Morgia G**, Cimino S, Di Mauro M, La Vignera S. J Endocrinol Invest. 2013 Oct;36(9):770-4. doi: 10.3275/8950. Epub 2013 Apr 30.
87. Endothelial progenitor cells and erectile dysfunction: a brief review on diagnostic significance and summary of our experience.
Condorelli RA, Calogero AE, Vicari E, Duca Y, Favilla V, **Morgia G**, Cimino S, La Vignera S. Aging Male. 2013 Jun;16(2):29-32. doi: 10.3109/13685538.2013.789159. Epub 2013 Apr 18. Review.
88. Expression of CD7, CD20 and CDX-2 in a secondary signet-ring cell tumor of the prostate: a case report.
Cimino S, Russo GI, Favilla V, Fragala E, Collura Z, Zanghi A, Castelli T, Madonia M, **Morgia G**. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):269-72.
89. Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia.
Minutoli L, Bitto A, Squadrito F, Marini H, Irrera N, **Morgia G**, Passantino A, Altavilla D. Curr Med Chem. 2013;20(10):1306-12. Review.
90. Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor.
La Vignera S, Condorelli RA, Vicari E, Lotti F, Favilla V, **Morgia G**, Maggi M, Calogero AE. Andrology. 2013 Mar;1(2):245-50. doi: 10.1111/j.2047-2927.2012.00025.x. Epub 2012 Nov 29.
91. Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive

- bladder carcinoma.
Serretta V, Altieri V, **Morgia G**, Di Lallo A, Carrieri G, Allegro R; Gruppo Studi Tumori Urologici (GSTU) Foundation.
Urology. 2013 Feb;81(2):277-81. doi: 10.1016/j.urology.2012.09.040.
92. Arterial erectile dysfunction: different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil.
Condorelli RA, Calogero AE, Favilla V, **Morgia G**, Johnson EO, Castiglione R, Salemi M, Mongioi L, Nicoletti C, Duca Y, Di Mauro M, Vicari E, La Vignera S.
Eur J Intern Med. 2013 Apr;24(3):234-40. doi: 10.1016/j.ejim.2013.01.001. Epub 2013 Jan 26.
93. Unusual presentation of tuberous sclerosis complex.
Favilla V, Cimino S, Castelli T, Marchese F, Russo GI, Russo M, Madonia M, **Morgia G**.
Urology. 2012 Oct;80(4):e39-40. doi: 10.1016/j.urology.2012.06.016. Epub 2012 Aug 15.
94. External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma.
Gontero P, Sun M, Antonelli A, Bertini R, Carini M, Carmignani G, Longo N, Martorana G, Minervini A, Mirone V, **Morgia G**, Novara G, Oderda M, Simeone C, Simonato A, Siracusano S, Tizzani A, Volpe A, Karakiewicz P, Ficarra V; Members of the SATURN Project–LUNA Foundation.
World J Urol. 2013 Oct;31(5):1285-90. doi: 10.1007/s00345-012-0896-z. Epub 2012 Jul 31.
95. Polyphenols: key issues involved in chemoprevention of prostate cancer.
Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, **Morgia G**.
Oxid Med Cell Longev. 2012;2012:632959. doi: 10.1155/2012/632959. Epub 2012 May 28. Review.
96. The relationship between oxidative stress and obesity in prostate disease.
Scavuzzo A, Favilla V, Cimino S, Madonia M, Li Volti G, **Morgia G**.
Urologia. 2012 Apr-Jun;79(2):156-8. doi: 10.5301/RU.2012.9206. Italian.
97. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Serretta V, Altieri V, **Morgia G**, Nicolosi F, De Grande G, Mazza R, Melloni D, Allegro R, Ferrau F, Gebbia V.
Clin Genitourin Cancer. 2012 Sep;10(3):174-9. doi: 10.1016/j.clgc.2012.03.002. Epub 2012 Apr 12.
98. Molecular pathways involved in the early and late damage induced by testis ischemia: evidence for a rational pharmacological modulation.
Altavilla D, Romeo C, Squadrito F, Marini H, **Morgia G**, Antonuccio P, Minutoli L.
Curr Med Chem. 2012;19(8):1219-24. Review.
99. Polydeoxyribonucleotide administration improves the intra-testicular vascularization in rat experimental varicocele.
Arena S, Minutoli L, Arena F, Nicotina PA, Romeo C, Squadrito F, Altavilla D, **Morgia G**, Magno C.
Fertil Steril. 2012 Jan;97(1):165-8. doi: 10.1016/j.fertnstert.2011.10.007. Epub 2011 Nov 17.
100. The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth.
Altavilla D, Bitto A, Polito F, Irrera N, Marini H, Arena S, Favilla V, Squadrito F, **Morgia G**, Minutoli L.
J Urol. 2011 Oct;186(4):1524-9. doi: 10.1016/j.juro.2011.05.049. Epub 2011 Aug 19
101. The association of Serenoa repens, lycopene and selenium is superior to Serenoa repens alone in

reducing benign prostatic hyperplasia.

Squadrito F, **Morgia G.**

Urologia. 2011 Oct-Dec;78(4):297-9. doi: 10.5301/RU.2011.8520. Italian.

102. Effects of polydeoxyribonucleotide on the histological damage and the altered spermatogenesis induced by testicular ischaemia and reperfusion in rats.
Minutoli L, Antonuccio P, Squadrito F, Bitto A, Nicotina PA, Fazzari C, Polito F, Marini H, Bonvissuto G, Arena S, **Morgia G**, Romeo C, Caputi AP, Altavilla D.
Int J Androl. 2012 Apr;35(2):133-44. doi: 10.1111/j.1365-2605.2011.01194.x. Epub 2011 Jun 8
103. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study.
Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G, Cosciani Cunico S, Fontana D, Longo N, Martorana G, Mirone V, **Morgia G**, Novara G, Roscigno M, Schiavina R, Serni S, Simeone C, Simonato A, Siracusano S, Volpe A, Zattoni F, Zucchi A, Carini M; SATURN Project-LUNA Foundation.
J Urol. 2011 May;185(5):1604-10. doi: 10.1016/j.juro.2010.12.048. Epub 2011 Mar 21.
104. Perineal-guided endoscopic extraction of ejaculatory duct stones to treat obstructive azoospermia.
Favilla V, Cimino S, Madonia M, Castelli T, Sortino G, Russo M, **Morgia G.**
Fertil Steril. 2011 Jun;95(7):2430.e11-4. doi: 10.1016/j.fertnstert.2011.01.146. Epub 2011 Feb 21.
105. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antineoplastic therapy Italian study.
Gontero P, Oderda M, Altieri V, Bartoletti R, Cai T, Colombo R, Curotto A, Di Stasi S, Maffezzini M, Tamagno S, Serretta V, Sogni F, Terrone C, Tizzani A, **Morgia G**, Mirone V, Carmignani G.
Urol Int. 2011;86(1):19-24. doi: 10.1159/000321926. Epub 2010 Dec 30.
106. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?
Morgia G.
Eur Urol. 2011 Mar;59(3):353-5; discussion 355. doi: 10.1016/j.eururo.2010.11.023. Epub 2010 Nov 24.
107. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study.
Bonvissuto G, Minutoli L, **Morgia G**, Bitto A, Polito F, Irrera N, Marini H, Squadrito F, Altavilla D.
Urology. 2011 Jan;77(1):248.e9-16. doi: 10.1016/j.urology.2010.07.514. Epub 2010 Dec 15.
108. Critical issues in chronic prostatitis.
Magri V, Perletti G, Bartoletti R, Cai T, Emelyanova I, Mehik A, **Morgia G**, Skerk V, Trinchieri A, Wagenlehner FM, Naber KG.
Arch Ital Urol Androl. 2010 Jun;82(2):75-82. Review.
109. Activation of adenosine A2A receptors by polydeoxyribonucleotide increases vascular endothelial growth factor and protects against testicular damage induced by experimental varicocele in rats.
Minutoli L, Arena S, Bonvissuto G, Bitto A, Polito F, Irrera N, Arena F, Fragalà E, Romeo C, Nicotina PA, Fazzari C, Marini H, Implatini A, Grimaldi S, Cantone N, Di Benedetto V, Squadrito F, Altavilla D, **Morgia G.**
Fertil Steril. 2011 Mar 15;95(4):1510-3. doi: 10.1016/j.fertnstert.2010.07.1047. Epub 2010 Aug 24.
110. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.

- Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, **Morgia G**.
BJU Int. 2010 Dec;106(11):1700-3. doi: 10.1111/j.1464-410X.2010.09459.x.
111. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with *Serenoa repens* plus selenium and lycopene (Profluss) versus *S. repens* alone: an Italian randomized multicenter-controlled study.
Morgia G, Mucciardi G, Galì A, Madonia M, Marchese F, Di Benedetto A, Romano G, Bonvissuto G, Castelli T, Macchione L, Magno C.
Urol Int. 2010;84(4):400-6. doi: 10.1159/000302716. Epub 2010 Mar 24.
112. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
Serretta V, **Morgia G**, Altieri V, Di Lallo A, Ruggiero G, Salzano L, Battaglia M, Falsaperla M, Zito A, Sblendorio D, Melloni D, Allegro R; members of Gruppo Studi Tumori Urologici (GSTU) Foundation.
BJU Int. 2010 Jul;106(2):212-7. doi: 10.1111/j.1464-410X.2009.09153.x. Epub 2010 Jan 11.
113. Molecular markers for prostatic cancer.
Castelli T, Cimino S, Magno C, **Morgia G**.
Front Biosci (Elite Ed). 2010 Jan 1;2:641-56. Review.
114. New advances in clinical biomarkers in testis cancer.
Favilla V, Cimino S, Madonia M, **Morgia G**.
Front Biosci (Elite Ed). 2010 Jan 1;2:456-77. Review.
115. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.
Serretta V, Altieri V, **Morgia G**, Siragusa A, De Grande G, Napoli M, Falsaperla M, Melloni D, Allegro R.
Urol Int. 2009;83(4):452-7. doi: 10.1159/000251187. Epub 2009 Dec 8.
116. A case of renal capsular liposarcoma with intracaval fat thrombus.
Ciccarello G, Mucciardi G, **Morgia G**, Spinelli F, Ascenti G, Macchione L, Magno C.
Eur Urol. 2010 Feb;57(2):350-3. doi: 10.1016/j.eururo.2009.07.021. Epub 2009 Jul 28.
117. Haemostatic agents during laparoscopic nephron-sparing surgery: what about TachoSil?
Falsaperla M, Autorino R, Puglisi M, Damiano R, Salerno GL, Motta M, **Morgia G**.
BJU Int. 2009 Jul;104(2):270-1. doi: 10.1111/j.1464-410X.2009.08750_3.x. No abstract available.
118. Vacuum-assisted closure for the treatment of Fournier's gangrene.
Cuccia G, Mucciardi G, **Morgia G**, Stagno d'Alcontres F, Galì A, Cotrufo S, Romeo M, Magno C.
Urol Int. 2009;82(4):426-31. doi: 10.1159/000218532. Epub 2009 Jun 8.
119. Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma.
Serretta V, Altieri V, **Morgia G**, Allegro R, Ruggirello A, Di Lallo A, Carrieri G, Melloni D; Members of the foundation Gruppo Studi Tumori Urologici (GSTU).
Urol Int. 2009;82(3):318-23. doi: 10.1159/000209365. Epub 2009 May 11.
120. CyberKnife in the treatment of prostate cancer: a revolutionary system.
Morgia G, De Renzis C.

- Eur Urol. 2009 Jul;56(1):40-2. doi: 10.1016/j.eururo.2009.02.020. Epub 2009 Feb 23.
121. Retrospective outcome analysis of one-stage penile urethroplasty using a flap or graft in a homogeneous series of patients.
Barbagli G, **Morgia G**, Lazzeri M.
BJU Int. 2008 Sep;102(7):853-60. doi: 10.1111/j.1464-410X.2008.07741.x. Epub 2008 May 15. Erratum in: BJU Int. 2008 Dec;102(11):1772.
122. Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients.
Magno C, Mucciardi G, Galì A, Anastasi G, Inferrera A, **Morgia G**.
Int Urol Nephrol. 2008;40(4):941-6. doi: 10.1007/s11255-008-9394-z. Epub 2008 May 14.
123. Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study.
Prezioso D, Bartoletti R, Cecchi M, Cicalese V, Cunico SC, Damiano R, De Lisa A, Franzolin N, Frea B, 81Guazzoni G, Mearini E, **Morgia G**, Muzzonigro G, Oliva G, Orestano F, Pagliarulo A, Pappagallo GL, Parma P, Perachino M, Pompa P, Rocco F, Zattoni F; QuABIOS Study Group.
Arch Ital Urol Androl. 2007 Sep;79(3):99-103
124. Dorsal onlay skin graft bulbar urethroplasty: long-term follow-up.
Barbagli G, **Morgia G**, Lazzeri M.
Eur Urol. 2008 Mar;53(3):628-33. Epub 2007 Aug 21.
125. Transurethral resection of prostate: technical progress by bipolar Gyrus plasma-kinetic tissue management system.
Falsaperla M, Cindolo L, Saita A, Polara A, Bonaccorsi A, Scavuzzo A, Motta M, **Morgia G**.
Minerva Urol Nefrol. 2007 Jun;59(2):125-9.
126. Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder. A study from Gruppo Studi Tumori Urologici Foundation.
Serretta V, **Morgia G**, Altieri V, Pavone-Macaluso M, Scuto F, Allegro R, Di Lallo A, Cindolo L, Melloni D; Gruppo Studi Tumori Urologici Foundation.
Urol Int. 2006;77(2):152-8.
127. Antibacterial prophylaxis in endourological procedures.
Prezioso D, Bartoletti R, Damiano R, **Morgia G**.
Minerva Urol Nefrol. 2006 Mar;58(1):73-80. Italian.
128. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.
Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, **Morgia G**, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R.
Kidney Int. 2006 Jul;70(1):177-86. Epub 2006 May 17.
129. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria.
Nosadini R, Velussi M, Brocco E, Abaterusso C, Carraro A, Piarulli F, **Morgia G**, Satta A, Faedda R, Abhyankar A, Luthman H, Tonolo G.
Diabetes. 2006 Jan;55(1):234-9.
130. Diagnosing erectile dysfunction: instruments for the study of smooth muscle relaxation.

- Pescatori ES, **Morgia G**, Pirozzi-Farina F.
Int J Androl. 2005 Dec;28 Suppl 2:56-60. Review. Erratum in: Int J Androl. 2005 Dec;28(6):380. Farina, FP
131. Use of alpha1-blockers in female functional bladder neck obstruction.
Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, **Morgia G**.
Urol Int. 2005;74(3):256-61.
132. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
Falsaperla M, **Morgia G**, Tartarone A, Ardito R, Romano G.
Eur Urol. 2005 Apr;47(4):449-54; discussion 454-5. Epub 2005 Jan 19.
133. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms.
Nosadini R, Velussi M, Brocco E, Abaterusso C, Piarulli F, **Morgia G**, Satta A, Faedda R, Abhyankar A, Luthman H, Tonolo G.
Diabetes. 2005 Jan;54(1):228-33.
134. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, Mazzarino MC.
Urol Res. 2005 Feb;33(1):44-50. Epub 2004 Oct 22.
135. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer.
Cardile V, Scifo C, Russo A, Falsaperla M, **Morgia G**, Motta M, Renis M, Imbriani E, Silvestre G.
Anticancer Res. 2003 Nov-Dec;23(6C):4921-6
136. Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 patients.
Serretta V, **Morgia G**, Fondacaro L, Curto G, Pirritano D, Lo Bianco A, Melloni D, Orestano F, Motta M, Pavone-Macaluso M; Members of the Sicilian-Calabrian Society of Urology.
Urol Int. 2003;71(1):16-21.
137. Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies.
Falsaperla M, **Morgia G**, Giammusso B, Condorelli SV, Saita A, Marchese F, Spampinato A, Motta M.
Prostate Cancer Prostatic Dis. 2003;6(1):45-9.
138. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions.
Serretta V, **Morgia G**, Fondacaro L, Curto G, Lo bianco A, Pirritano D, Melloni D, Orestano F, Motta M, Pavone-Macaluso M; Members of the Sicilian-Calabrian Society of Urology.
Urology. 2002 Oct;60(4):623-7.
139. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.
Raffaele R, Vecchio I, Giammusso B, **Morgia G**, Brunetto MB, Rampello L.
Eur Urol. 2002 Apr;41(4):382-6.
140. Mepartricine and prostatitis. Clinical experience and rationale for use.
Saita A, **Morgia G**, Branchina A, Giammusso B, Iurato C, Malacasa E, Motta M.
Minerva Urol Nefrol. 2001 Sep;53(3):129-33. Italian
141. Management of patients with LUTS suggestive of BPH.

- Gentile M, Carini M, **Morgia G**, Selvaggi FP, Randone D, Rosati A.
Eur Urol. 2001;40 Suppl 1:5-8
142. Immunohistochemical and molecular analysis in recurrent urethral stricture.
Morgia G, Saita A, Falsaperla M, Spampinato A, Motta M, Cordaro S.
Urol Res. 2000 Oct;28(5):319-22
143. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients.
Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, Breda G, Silvestre P, Giammusso B, **Morgia G**, Graziottin A.
Eur Urol. 2000 Jan;37(1):50-5.
144. Endoprosthesis implantation in the treatment of recurrent urethral stricture: a multicenter study. Sicilian-Calabrian Urology Society.
Morgia G, Saita A, Morana F, Macaluso CP, Serretta V, Lanza P, Capizzi G, Calarco A, Zumbo G.
J Endourol. 1999 Oct;13(8):587-90.
145. Treatment of unusual testicular tumors.
Motta M, **Morgia G**, Saita A.
Arch Ital Urol Androl. 1997 Feb;69 Suppl 1:3-7. Review. Italian
146. Paroxetine in the treatment of premature ejaculation.
Giammusso B, **Morgia G**, Spampinato A, Motta M.
Arch Ital Urol Androl. 1997 Feb;69(1):11-3. Italian.
147. Focus on the role of PSA. Data of the observational UroLink study.
Morgia G.
Arch Ital Urol Androl. 1997;69(5 Suppl):11-4. Italian.
148. Use of stents in postoperative recurrent urethral stenosis.
Morgia G, Saita A, Spampinato A, Motta M.
Arch Ital Urol Androl. 1995 Sep;67(4):269-71. Italian.
149. Retrospective survey of pharmacologic tolerance in the prevention of neoplastic recurrence of superficial urothelioma.
Morgia G, Mauceri G, Mazzone G, Motta M.
Arch Ital Urol Nefrol Androl. 1992 Dec;64(4):313-7. Italian.
150. Uroflowmetry in the early diagnosis of postoperative urethral stenosis.
Morgia G, Costanzo V, Giammusso B, Fondacaro L, Motta M.
Minerva Urol Nefrol. 1992 Jul-Sep;44(3):173-6. Italian.
151. Extracorporeal shock wave lithotripsy for urinary stone disease: our experience.
Morgia G, Costantino G, Nicosia A, Giammusso B, Motta M.
Arch Ital Urol Nefrol Androl. 1992 Jun;64(2):183-6.

ATTIVITÀ DI REFEREE Urologia Internationalis, Journal of Sexual Medicine, European Urology Supplements, Andrology, Evidence-Based Complementary and Alternative Medicine

PARTECIPAZIONI IN SOCIETÀ SCIENTIFICHE DEL SETTORE

2004-2008 Membro del ESU Board Committee dell'European Association of Urology
Anni 2010-2013 Presidente del CdA della Fondazione L.U.N.A. (Leading Urological No profit foundation Advanced research) – ONLUS” della SIU (Società Italiana di Urologia)
Anni 2014-2017 Membro del Comitato Esecutivo della Società Italiana d’Urologia
Dal 2015 sino ad oggi Delegato Italiano della Società Internazionale d’Urologie

PREMI ACCADEMICI

Agosto 2008 VII Premio “Fiore di Zagara” alle Professionalità Siciliane

Catania, 11/04/2016

Prof. G. Morgia
